Product Introduction :
Dacomtinib is a new anti-cancer drug developed by Pfizer. The single agent is approved for the first-line treatment of locally advanced or metastatic NSCLC patients with EGFR exon 19 deletion mutation or exon 21 L858R substitution mutation.
Dacomitinib belongs to the second-generation EGFR targeted drug for lung cancer, and its efficacy is far better than the first-generation targeted drugs such as Iressa. The median progression-free survival of Iressa is 9.2 months, i.e. when patients are treated for 9.2 months, half of them are drug-resistant, and the disease has begun to progress. The median progression-free survival of dacomitinib is 14.7 months, which is longer than Iressa by more than 5 months. The median progression-free survival of dacomitinib reaches 18.4 months in Chinese patients.
The American Society of Clinical Oncology (ASCO) released data in the 2018 annual meeting. If patients with advanced lung cancer carrying EGFR-sensitive gene mutations are treated with dacomitinib, their average overall survival is 34.1 months, close to 3 years.
Dacomtinib is indicated for the treatment of NSCLC patients with EGFR exon 19 deletion mutation or exon 21 L858R substitution mutation.
Administration and Dosage :
Dacomtinib is taken orally at a recommended dose of 45 mg each day, once a day.